TRB-N0224

Biotech September 27, 2017

NIH sees a need for speed in Traverse Biosciences

By GREGORY ZELLER // The National Institutes of Health has welcomed a rising Stony Brook biotech into its competitive Commercialization Accelerator Program. Traverse Biosciences, which is attempting to commercialize novel drug candidates for the treatment of inflammatory diseases affecting animals and humans, has landed one of 80 annual slots in the CAP, a nine-month program hosted by the NIH and the Larta Institute, a California-based networking group promoting international innovation. The NIH CAP – which…

Biotech February 14, 2017

New patent, new partnership for soaring Traverse

By GREGORY ZELLER // When a new U.S. patent is your second-biggest announcement of the day, you’re probably in a good place. It’s all smiles (with healthy teeth, of course) lately at Stony Brook-based Traverse Biosciences, which on Tuesday announced a new patent and a material transfer agreement with what CEO Joseph Scaduto dubbed “a top-10 global animal-health company” – essentially, an agreement to privately test flagship formula TRB-N0224 against a host of animal illnesses. That’s…

Biotech August 16, 2016

Traverse sinks teeth into human periodontal study

By GREGORY ZELLER // It seems everyone wants a piece of TRB-N0224. Already being tested as a potential treatment for lung injuries and for periodontal disease in dogs and cats, the flagship formula patented by Stony Brook-based Traverse Biosciences will now be pitted against inflammatory diseases threating bone and tissue around human teeth. The National Institutes of Health has awarded Traverse Biosciences, in partnership with Stony Brook University’s School of Dental Medicine, a $1.32 million…

Biotech July 11, 2016

Traverse, SUNY, DoD set big test for TRB-N0224

Stony Brook-based biotech Traverse Biosciences will share a Department of Defense award with SUNY Upstate Medical University to fund a critical field test of Traverse’s leading drug candidate. The effectiveness of TRB-N0224 as a treatment for lung injuries – including acute respiratory distress syndrome, a common condition in critically ill patients with a mortality rate as high as 50 percent – will be put to the test via a DoD Peer Reviewed Medical Research Program…